2. Search Result
Search Result
Results for "

TNF-α/TNFR1

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

4

Peptides

3

Inhibitory Antibodies

1

Protéines recombinantes

1

Antibodies

Targets Recommended:
Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-P9970
    Infliximab
    25+ Cited Publications

    Avakine; CT-P13; SB2; TA-650

    		 TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    The component ratio of this product is Active ingredient : Excipients = 9 : 47.
    Infliximab
  • HY-160412
    Balinatunfib

    SAR-441566; TNFα activity modulator 3

    		 TNF Receptor Inflammation/Immunology
    Balinatunfib (SAR-441566) is an orally active inhibitor of TNFR1 signaling. By binding to the central pocket of the soluble TNFα (sTNFα) trimer, Balinatunfib stabilizes an asymmetric conformation, blocking its binding to TNFR1 (without affecting TNFR2) and thus inhibiting downstream pathways. Balinatunfib has anti-inflammatory activity, and can be used in the study of autoimmune diseases .
    Balinatunfib
  • HY-P9970A
    Infliximab (Anti-TNF-α)

    Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)

    		 TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab (Anti-TNF-α)
  • HY-111255
    SPD304
    5+ Cited Publications

    		 TNF Receptor Cancer
    SPD304 is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .
    SPD304
  • HY-134471
    TNF-α-IN-2
    1 Publications Verification

    		 TNF Receptor Inflammation/Immunology Cancer
    TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα), with an IC50 of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1. TNF-α-IN-2 can be used for the research of rheumatoid arthritis .
    TNF-α-IN-2
  • HY-133807
    Benpyrine
    3 Publications Verification

    		 TNF Receptor Inflammation/Immunology
    Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 µM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research .
    Benpyrine
  • HY-P991400
    GSK1995057

    		TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK Inflammation/Immunology
    GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .
    GSK1995057
  • HY-111255A
    SPD304 dihydrochloride
    5+ Cited Publications

    		 TNF Receptor Inflammation/Immunology Cancer
    SPD304 dihydrochloride is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α .
    SPD304 dihydrochloride
  • HY-P11108
    RP-182

    		NF-κB Apoptosis TNF Receptor Caspase Inflammation/Immunology Cancer
    RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .
    RP-182
  • HY-118922
    IW927

    		TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    IW927 is a photochemically enhanced TNF-α-TNFR1 interaction inhibitor that blocks the binding of TNF-α to TNFRc1 with an IC50 value of 50 nM. IW927 binds reversibly to the TNFRc1 with weak affinity (Kd = 40-100 μM), covalently modifies the receptor via a photochemical reaction, and does not bind the related cytokine receptors TNFRc2 or CD40. IW927 disrupts TNFα-induced IκB phosphorylation with an IC50 value of 600 nM. IW927 can be used to develop light-independent inhibitors .
    IW927
  • HY-P2612
    WP9QY

    		TNF Receptor RANKL/RANK Apoptosis Inflammation/Immunology
    WP9QY is an inhibitor targeting TNFα and RANKL, which blocks the TNFα-TNFR1 interaction and inhibits TNFα-mediated apoptosis, cytotoxicity and bone destruction. WP9QY inhibits osteoclastogenesis and promotes osteoblast differentiation, induces chondrocyte proliferation and glycosaminoglycan production, and synergizes with TGF-β3 to promote chondrogenesis. WP9QY effectively repairs full-thickness articular cartilage defects in rabbits via intra-articular injection, and inhibits methylmercury-induced reduction of NeuN-positive cells in mouse brain slices. WP9QY can be applied to the research of diseases related to methylmercury-induced neuronal death, cartilage injury, osteoarthritis and bone loss .
    WP9QY
  • HY-124339
    JNJ525

    		TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    JNJ525 is a TNFα inhibitor with IC50 values of 1.2 μM and 1.1 μM against TNFR1 and TNFR2, respectively. JNJ525 forms ordered aggregates and induces quaternary structural transition of TNFα, thereby blocking the protein-protein interaction between TNFα and its receptors. The inhibitory activity of JNJ525 is completely lost in the presence of 0.1% Triton X-100 .
    JNJ525
  • HY-P11214
    Hydrostatin-TL1

    H-TL1

    		 TNF Receptor Integrin NF-κB ERK p38 MAPK JNK Interleukin Related Inflammation/Immunology
    Hydrostatin-TL1 (H-TL1), a nine-amino-acid peptide, is a TNF-α antagonist. Hydrostatin-TL1 can be isolated from the venom gland of sea snake Hydrophis cyanocinctus. H-TL1 competitively inhibits the interaction between TNF-α/TNFR1 and attenuates the cytotoxicity and inflammation of TNF-α. Hydrostatin-TL1 can be used for TNF-α-associated inflammatory diseases, such as rheumatoid arthritis, osteoporosis and inflammatory bowel disease (IBD) research .
    Hydrostatin-TL1
  • HY-133807B
    (R)-Benpyrine

    		TNF Receptor Inflammation/Immunology
    (R)-Benpyrine is the isomer of Benpyrine (HY-133807), and can be used as an experimental control. Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 μM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research .
    (R)-Benpyrine
  • HY-119420
    Acetoxycycloheximide

    		Antibiotic Apoptosis Caspase JNK p38 MAPK TNF Receptor ERK NF-κB Mitochondrial Metabolism Inflammation/Immunology Cancer
    Acetoxycycloheximide is an antibiotic with antitumor activity. Acetoxycycloheximide a protein synthesis inhibitor. Acetoxycycloheximide significantly induces activation of procaspase-3 and subsequent apoptosis mediated by the Cytochrome c from mitochondria via activation of JNK pathway. Acetoxycycloheximide triggers the downregulation of cell surface TNF-R1 via the activation of ERK and p38 MAPK, thereby preventing activation of the NF-κB signaling pathway by TNF-α. Acetoxycycloheximide is much more toxic to female rats than to males. Acetoxycycloheximide can be used for inflammatory and immune diseases and cancers research .
    Acetoxycycloheximide
  • HY-178053
    AHR agonist 10

    		Aryl Hydrocarbon Receptor Cytochrome P450 Interleukin Related Inflammation/Immunology
    AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research .
    AHR agonist 10
  • HY-P11108A
    RP-182 acetate

    		NF-κB Apoptosis TNF Receptor Caspase Inflammation/Immunology Cancer
    RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 acetate induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 acetate has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 acetate is used in pancreatic cancer and melanoma research .
    RP-182 acetate
  • HY-182884
    TNF-α-IN-29

    		TNF Receptor Inflammation/Immunology
    TNF-α-IN-29 is an orally active and selective TNF-α inhibitor, with IC50 values of 123.0 nM against human targets, and a human Kd of 45.9 nM. TNF-α-IN-29 blocks TNF-α-TNFR1 protein-protein interactions and inhibits TNF-α-mediated inflammatory signaling pathways. TNF-α-IN-29 exhibits anti-inflammatory effects in a mouse model of collagen-induced arthritis and promotes articular cartilage repair. TNF-α-IN-29 can be used for the research of rheumatoid arthritis .
    TNF-α-IN-29

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: